TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31892680

Group type: EXPERIMENTAL
Intervention: Anesthetic Chewing Gum (ACG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chewing Gum (CG) without anesthetics
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no CG)
Number of subjects: 60
Study: 30348739

Group type: COMPARATOR
Intervention: Control (general immunization information)
Number of subjects: 3420

Group type: EXPERIMENTAL
Intervention: Pain pamphlet (pain mitigation information)
Number of subjects: 3420

Group type: EXPERIMENTAL
Intervention: Pain pamphlet and pain video (pain mitigation information)
Number of subjects: 3420
Study: 27846344

Group type: EXPERIMENTAL
Intervention: Evolocumab (420 mg monthly for 76 weeks)
Number of subjects: 968

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968
Study: 22840762

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) treatment to the left temporoparietal cortex for 10 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 30
Study: 20820916

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400 mg twice daily
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study: 18549466

Group type: EXPERIMENTAL
Intervention: Testosterone gel (TG)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone gel (DHTG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No replacement (NoRx)
Number of subjects: 12
Study: 17299466

Group type: EXPERIMENTAL
Intervention: Daily low-dose vitamin A (5000 IU per day)
Number of subjects: 1214

Group type: COMPARATOR
Intervention: Single high-dose vitamin A (200,000 IU)
Number of subjects: 1214
Study: 15144910

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 921

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 921
Study: 11292011

Group type: EXPERIMENTAL
Intervention: Ayahuasca (0.5 mg DMT/kg body weight)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ayahuasca (0.75 mg DMT/kg body weight)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ayahuasca (1.0 mg DMT/kg body weight)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ayahuasca (all doses)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ayahuasca (medium dose)
Number of subjects: 6
Study: 9331003

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (8, 12, or 16 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil with HCTZ
Number of subjects: 0
Study: 7898993

Group type: EXPERIMENTAL
Intervention: Intermittent exercise and relaxation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continuous exercise
Number of subjects: 10
Study: 3221745

Group type: EXPERIMENTAL
Intervention: (R)-propafenone 250 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: (S)-propafenone 250 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: (R)-propafenone in poor hydroxylator
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: (S)-propafenone in poor hydroxylator
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Both enantiomers
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: (R)-propafenone in efficient hydroxylators
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: (S)-propafenone in efficient hydroxylators
Number of subjects: 7
Study: 30001760

Group type: EXPERIMENTAL
Intervention: Step 15 exposure therapy (allowing a spider to walk freely over one's body)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Step 14 or fewer exposure therapy steps
Number of subjects: 51
Study: 26599991

Group type: EXPERIMENTAL
Intervention: EEG biofeedback (neurofeedback) training to increase left anterior theta power (NF‐HYP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Relaxation control condition (RLX‐HYP)
Number of subjects: 20
Study: 25720854

Group type: EXPERIMENTAL
Intervention: ASR implants
Number of subjects: 46

Group type: COMPARATOR
Intervention: ReCap implants
Number of subjects: 46
Study: 22642937

Group type: EXPERIMENTAL
Intervention: tibolone
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: raloxifene
Number of subjects: 89

Group type: COMPARATOR
Intervention: no treatment (control)
Number of subjects: 89
Study: 22147343

Group type: EXPERIMENTAL
Intervention: Chinese preparation of rhGH (GenHeal®, 1.6 mg (4 IU), Shanghai, China) administered at a dose of 0.1 IU/kg body weight, one injection per day for 14 days.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Swiss preparation of rhGH (Saizen®, 1.33 mg (4 IU), Laboratoires Serone S.A., Switzerland) administered at a dose of 0.1 IU/kg body weight, one injection per day for 14 days.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo group (6 volunteers).
Number of subjects: 25
Study: 18972290

Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate (BDP; 400 microg/d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 19952770

Group type: EXPERIMENTAL
Intervention: Additional walking
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cycle ergometry training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation program
Number of subjects: 60
Study: 15614573

Group type: EXPERIMENTAL
Intervention: 0.42 mg/kg dexamphetamine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12168743

Group type: EXPERIMENTAL
Intervention: One-arm hop test for football players
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: One-arm hop test for wrestlers
Number of subjects: 26
Study: 9537786

Group type: EXPERIMENTAL
Intervention: Capsaicin nasal challenge
Number of subjects: 3

Group type: COMPARATOR
Intervention: Vehicle nasal challenge
Number of subjects: 3
Study: 8032830

Group type: EXPERIMENTAL
Intervention: Evans BCG
Number of subjects: 99

Group type: COMPARATOR
Intervention: Pasteur BCG
Number of subjects: 99
Study: 2645120

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 235

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 235
Study: 11968802

Group type: EXPERIMENTAL
Intervention: Clinical pathway group (32 patients)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Non-pathway group (37 patients)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 69
Study: 29858133

Group type: EXPERIMENTAL
Intervention: Caudal epidural block (CEB) plus general anesthesia (GA)
Number of subjects: 57

Group type: COMPARATOR
Intervention: General anesthesia (GA) only
Number of subjects: 57
Study: 27542357

Group type: EXPERIMENTAL
Intervention: Smart Moms intervention (6-month smartphone-delivered program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 23983274

Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP)
Number of subjects: 553

Group type: COMPARATOR
Intervention: Tobramycin inhalation solution (TIS)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Both TIP and TIS
Number of subjects: 553
Study: 22030902

Group type: EXPERIMENTAL
Intervention: Quantitative liver function tests (QLFTs)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Galactose elimination capacity (GEC)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Dual cholate (CA) clearance after oral administration (Cl(oral))
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Caffeine elimination rate (k(elim)), antipyrine (AP) clearance (Cl), MEGX concentration, methionine breath test (MBT), galactose elimination capacity (GEC), dual cholate (CA) clearances and shunt, perfused hepatic mass (PHM), and liver and spleen volumes
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: CA Cl(oral) or PHM
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Low risk QLFTs
Number of subjects: 227
Study: 20585735

Group type: EXPERIMENTAL
Intervention: Indoor cycling (CI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Indoor cycling combined with low-calorie diet (CD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (D)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 40
Study: 17916068

Group type: EXPERIMENTAL
Intervention: Dynamic irrigation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Static irrigation
Number of subjects: 40
Study: 15983093

Group type: EXPERIMENTAL
Intervention: 10% dextrose (5 g in 50 ml)
Number of subjects: 51

Group type: COMPARATOR
Intervention: 50% dextrose (5 g in 10 ml)
Number of subjects: 51
Study: 12915671

Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg twice daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 10700785

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2% mepivacaine
Number of subjects: 60
Study: 8520499

Group type: EXPERIMENTAL
Intervention: Myeloablative therapy supported by autologous bone marrow or blood stem cell transplantation
Number of subjects: 41
Study: 1836486

Group type: EXPERIMENTAL
Intervention: Accelerated vaccination schedule with recombinant hepatitis B vaccine (Engerix-B)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Conventional vaccination regimen
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Accelerated vaccination schedule
Number of subjects: 132
Study: 6769666

Group type: EXPERIMENTAL
Intervention: Sodium valproate (500 mg) in fasting (A)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sodium valproate (500 mg) with a meal (B)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sodium valproate (500 mg) 3 hours after a meal (C)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous bolus dose of VPA (400 mg) 3 hours after a meal
Number of subjects: 6
Study: 30895706

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES) in diabetics
Number of subjects: 1497

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS) in diabetics
Number of subjects: 1497

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES) in nondiabetics
Number of subjects: 1497

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS) in nondiabetics
Number of subjects: 1497

Group type: EXPERIMENTAL
Intervention: Overall outcomes in diabetics
Number of subjects: 1497
Study: 29742263

Group type: EXPERIMENTAL
Intervention: RMGIC + 4.5% DOX
Number of subjects: 0

Group type: COMPARATOR
Intervention: RMGIC (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RMGIC + 1.5% DOX
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RMGIC + 3% DOX
Number of subjects: 0
Study: 27574418

Group type: EXPERIMENTAL
Intervention: Self-management program (group education session, individual training on inhalation techniques, written action plan)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 0
Study: 25243929

Group type: EXPERIMENTAL
Intervention: Community health volunteers
Number of subjects: 5643

Group type: COMPARATOR
Intervention: Care seeking from an appropriate provider
Number of subjects: 5643
Study: 22861171

Group type: EXPERIMENTAL
Intervention: Completion of tool before regularly scheduled visit
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 135
Study: 21186964

Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 131
Study: 17295569

Group type: EXPERIMENTAL
Intervention: Schema-focused therapy (SFT)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Transference-focused psychotherapy (TFP)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Early treatment negative ratings
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Positive ratings in the 1st half of treatment
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Dissimilarity in pathological personality characteristics
Number of subjects: 78
Study: 16232343

Group type: EXPERIMENTAL
Intervention: 0.5 mg of Bacillus Calmette‐Guérin polysaccharide nucleotide (BCG‐PSN)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1 mg of BCG‐PSN
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.5 mg of BCG‐PSN (36 times)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 120
Study: 12199724

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Lamotrigine (LTG)
Number of subjects: 291
Study: 11793634

Group type: EXPERIMENTAL
Intervention: Celecoxib as adjunctive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 10530098

Group type: EXPERIMENTAL
Intervention: Braun Oral‐B Ultra Plaque Remover (D9)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Braun Oral‐B 3D Plaque Remover (3D)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Both toothbrushes
Number of subjects: 49
Study: 7993328

Group type: EXPERIMENTAL
Intervention: Worry suppression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-worrying thought
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Priming condition
Number of subjects: 0
Study: 2727071

Group type: EXPERIMENTAL
Intervention: Developmental physical therapy program (six one-minute activities in side-lying and supported-sitting positions)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Developmental physical therapy program
Number of subjects: 14
Study: 799561

Group type: EXPERIMENTAL
Intervention: Metoprolol (75-300 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31483155

Group type: EXPERIMENTAL
Intervention: Acute antioxidant (AO) administration (600 mg α-lipoic acid, 1,000 mg vitamin C, and 600 IU vitamin E)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Acute antioxidant (AO) administration
Number of subjects: 16
Study: 29138135

Group type: EXPERIMENTAL
Intervention: Endovascular strategy (316 patients, 275 with confirmed rupture)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Open repair (297 patients, 261 with confirmed rupture)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Endovascular strategy (502 patients with repaired ruptures)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Open repair (502 patients with repaired ruptures)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Endovascular strategy
Number of subjects: 613

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 613
Study: 26176018

Group type: EXPERIMENTAL
Intervention: NiTi heat-activated arch wires
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional NiTi arch wires
Number of subjects: 22
Study: 23117679

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Systemic eosinophil increase
Number of subjects: 78
Study: 21689115

Group type: EXPERIMENTAL
Intervention: Test shampoo
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study: 19112337

Group type: EXPERIMENTAL
Intervention: Bryan Cervical Disc
Number of subjects: 463

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion
Number of subjects: 463
Study: 16461147

Group type: EXPERIMENTAL
Intervention: Peanut flour (doses ranging from 10 microg to 3 g)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Peanut flour (doses ranging from 10 mg to 3 g)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dietary management over a 12-month period
Number of subjects: 27
Study: 15238773

Group type: EXPERIMENTAL
Intervention: Oral ALCAR (1500 mg twice daily) for up to 33 months
Number of subjects: 21
Study: 11753499

Group type: EXPERIMENTAL
Intervention: Nutritional education program (9 sessions of one hour each over one year)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (no nutritional sessions, normal follow-up advice)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Nutritional education program
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 151
Study: 9300221

Group type: EXPERIMENTAL
Intervention: Recombinant human insulin-like growth factor-1 (rhIGF-I)
Number of subjects: 0
Study: 8363210

Group type: EXPERIMENTAL
Intervention: Intrapersonal standard deviation of weight (ISD) quartiles
Number of subjects: 10529
Study: 3534801

Group type: EXPERIMENTAL
Intervention: 12.5 mg hydrochlorothiazide
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 112.5 mg hydrochlorothiazide
Number of subjects: 9
Study: 30890817

Group type: EXPERIMENTAL
Intervention: Motivational interviewing sessions (4 sessions, 15-20 minutes each)
Number of subjects: 60
Study: 29957362

Group type: EXPERIMENTAL
Intervention: Cooling intervention leg cuff
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo cuff (control)
Number of subjects: 276
Study: 26880373

Group type: EXPERIMENTAL
Intervention: Multicomponent program of discomfort reduction implemented over 6 months, including identification of discomforts, immediate feedback to the healthcare team, and implementation of targeted interventions.
Number of subjects: 660

Group type: COMPARATOR
Intervention: Control group with no specific program implemented over 6 months.
Number of subjects: 660
Study: 25203376

Group type: EXPERIMENTAL
Intervention: Bioabsorbable staple line reinforcement
Number of subjects: 302

Group type: COMPARATOR
Intervention: Stapled circular anastomosis without reinforcement
Number of subjects: 302
Study: 22709745

Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pumping (IABP) in addition to early revascularization (either percutaneous coronary intervention or coronary artery bypass grafting)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Optimal medical therapy on the background of early revascularization (either percutaneous coronary intervention or coronary artery bypass grafting)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: IABP
Number of subjects: 600

Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 600
Study: 21164555

Group type: EXPERIMENTAL
Intervention: Tap water (W)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Flavored water (FW)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Flavored water with 6% carbohydrate and 18 mmol·L‐1 NaCl (CNa)
Number of subjects: 8
Study: 17623067

Group type: EXPERIMENTAL
Intervention: Hot compresses on the right upper abdomen
Number of subjects: 13

Group type: COMPARATOR
Intervention: No hot compresses
Number of subjects: 13
Study: 15590226

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral program (CBP)
Number of subjects: 16
Study: 12799509

Group type: EXPERIMENTAL
Intervention: 9-valent pneumococcal conjugate vaccine (PnCRM9)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control vaccine (meningococcus C vaccine)
Number of subjects: 262
Study: 10423078

Group type: EXPERIMENTAL
Intervention: Newer classes of blood pressure lowering drugs
Number of subjects: 270000

Group type: COMPARATOR
Intervention: Blood pressure lowering treatments
Number of subjects: 270000
Study: 8558725

Group type: EXPERIMENTAL
Intervention: Supervised treadmill training (3 hr/wk at a work intensity sufficient to produce claudication)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Supervised treadmill training continued for an additional 12 weeks
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Strength training (3 hr/wk of resistive training of six muscle groups of each leg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Twelve weeks of treadmill training after the strength training program
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Twelve weeks of combined treadmill and strength training after the control period
Number of subjects: 29
Study: 1873659

Group type: EXPERIMENTAL
Intervention: Iotrolan (300 mgI/%),
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urografin (370 mgI/%),
Number of subjects: 0
Study: 6223946

Group type: EXPERIMENTAL
Intervention: Behavioral Therapy (BT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Physical Therapy (PT)
Number of subjects: 25
Study: 2580164

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 24

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Captopril and Enalapril (combined therapy)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Captopril and Enalapril (after prolonged treatment)
Number of subjects: 24
Study: 30827252

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN) procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 0
Study: 30017552

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (75–100 mg)
Number of subjects: 117279

Group type: EXPERIMENTAL
Intervention: Higher doses of aspirin (≥325 mg)
Number of subjects: 117279

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 117279
Study: 26713666

Group type: EXPERIMENTAL
Intervention: Lateral pararectal stoma placement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transrectal stoma placement
Number of subjects: 60
Study: 24201303

Group type: EXPERIMENTAL
Intervention: Conventional programming with therapy for ventricular tachycardia ≥170 bpm
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: High-rate cutoff with therapy for ventricular tachycardia ≥200 bpm and a monitoring zone at 170 to 199 bpm
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Prolonged 60-second delay with a monitoring zone before therapy
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Syncope (all types)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Clinical risk factors for syncope
Number of subjects: 1500
Study: 23128163

Group type: EXPERIMENTAL
Intervention: AMG145 280 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: AMG145 350 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: AMG145 420 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: AMG145 420 mg + Ezetimibe 10 mg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo + Ezetimibe 10 mg
Number of subjects: 160
Study: 21410069

Group type: EXPERIMENTAL
Intervention: Menatetrenone (4 5mg daily, orally)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40